Jacobs Engineering Group Inc.
(NYSE:JEC) announced today that a project it executed on behalf of
received a 2013 Facility of the Year Award (FOYA) from the International Society for Pharmaceutical Engineering (ISPE), INTERPHEX and Pharmaceutical Processing magazine, sponsors of the awards program.
The U.S. Flu Cell Culture Facility at the Novartis Campus in Holly Springs, N.C. received the FOYA for Process Innovation. The facility uses an innovative cell culture technology to manufacture seasonal and pandemic influenza vaccines. Judges cited the creative solution of containment convertibility that allows the facility to run at lower levels to reduce operating costs during routine seasonal influenza production, yet still maintain the capability of operating at higher containment levels when required. Jacobs provided design services, engineering, procurement and construction management for the facility.
In making the announcement, Jacobs Group Vice President Bob Pragada stated, “It was a privilege to work with Novartis on their award-winning facility. We appreciate their continued trust in us, and value our long-standing relationship.”
program recognizes pharmaceutical manufacturing projects that use new and innovative technologies to enhance project delivery and reduce production costs of high quality medicines for patients worldwide. Another Jacobs project was named the overall winner of the 2012 award.
Jacobs is one of the world's largest and most diverse providers of technical, professional, and construction services.
Statements made in this release that are not based on historical fact are forward-looking statements. We base these forward-looking statements on management’s current estimates and expectations as well as currently available competitive, financial and economic data. Forward-looking statements, however, are inherently uncertain. There are a variety of factors that could cause business results to differ materially from our forward-looking statements. For a description of some of the factors which may occur that could cause actual results to differ from our forward-looking statements please refer to our 2012 Form 10-K, and in particular the discussions contained under Items 1 - Business, 1A - Risk Factors, 3 - Legal Proceedings, and 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations. We do not undertake to update any forward-looking statements made herein.